NovaBiotics
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Silverburn Don Cres, Aberdeen, Aberdeens...Phone Number
+44 1224711377Website
www.novabiotics.co.ukRevenue
<$5 MillionIndustry
About NovaBiotics
Is NovaBiotics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once NovaBiotics has new funding data
Click to see if NovaBiotics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at NovaBiotics
Check if NovaBiotics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when NovaBiotics launches new products
NovaBiotics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on NovaBiotics recently announced quarterly report
Check out if NovaBiotics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined NovaBiotics as Masked Content
Find 2 more new buyers
Compare Similar Companies to NovaBiotics
Compare insights from companies similar to NovaBiotics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
NovaBiotics
Company Profile Activity
Activity Insights
NovaBiotics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NovaBiotics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NovaBiotics.
NovaBiotics financials insights
Gather financial insights about NovaBiotics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Private Equity
$7.6M
Private Equity
$3.7M
NovaBiotics Tech Stack
A closer look at the technologies used by NovaBiotics
NovaBiotics News & Media
NovaBiotics to Present at the H.C. Wainwright BioConnect Conference
ABERDEEN, Scotland, Jan. 4, 2022 /PRNewswire/ -- NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting-diseases, today announced that Deborah O'Neil, PhD, OBE, FRSE, Chief Executive Officer of NovaBiotics,...NovaBiotics Announces First Patient Enrollment into the Cysteamine Domain of REMAP-CAP
ABERDEEN, Scotland, Dec. 8, 2021 /PRNewswire/ -- NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting-diseases, today announced that the first patient has been enrolled into the Randomised, Embedded,...NovaBiotics to Present New Data at Upcoming North American Cystic Fibrosis Conference
ABERDEEN, Scotland, Oct. 29, 2021 /PRNewswire/ -- NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting diseases, announces that they will present two posters highlighting new preclinical data on cysteamine...NovaBiotics to Present Preclinical Data on NP339 and Sponsor Symposium on New Antifungals at Upcoming 10th Congress on Trends in Medical Mycology
ABERDEEN, Scotland, Oct. 5, 2021 /PRNewswire/ -- NovaBiotics Ltd, a privately held clinical stage company developing novel immune based therapies for life-threatening and life-limiting diseases, announces that the Company will co-sponsor a symposium on new antifungals in which Deborah...
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NovaBiotics
NovaBiotics, founded in 2004 and headquartered in Aberdeen, UK, is a leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.... Read More